Butyrate for Health & Longevity
Evidence Review created on 09/26/2026 using AI4L + evidence-mcp / Grok 4.5
Also known as: Butyric Acid, Butanoic Acid, Butanoate, Sodium Butyrate
Motivation
Butyrate, also called butyric acid, is a small fatty acid. Colon bacteria make it when they ferment fiber that human enzymes do not digest, and it is also sold as sodium or calcium salts and as tributyrin, a fat that releases butyrate after digestion. Colon cells burn it for energy. That local role, plus signals that affect inflammation, gut sealing, and appetite hormones, is why it draws interest from people working on long-term metabolic and gut health.
Enemas were an early attempt to replace a suspected fuel shortage in ulcerative colitis, with mixed results. Oral capsules came later, aimed at passing the stomach. Recent trials have looked at bowel symptoms, body weight, and blood pressure. Some of those results favor butyrate, some do not, and several depend on who was studied and which chemical form was used.
This review examines the human evidence on butyrate for health and longevity: how it acts, what benefits and harms have actually been measured, how trials have dosed it, and what remains a mechanism or an animal finding rather than a measured human outcome.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Overviews that discuss butyrate itself, or the fiber fermentation that produces it, from priority educators and a longevity publication.
-
Butyrate - FoundMyFitness
A short topic page on microbial butyrate as colon-cell fuel, and on permeability, glucose tolerance, inflammation, exercise, and fasting.
-
RHR: Gut Health 3.0- The Power of Polyphenols and Postbiotics - Chris Kresser
Clinician overview of butyrate as a postbiotic, including why many oral forms are poorly delivered to the colon. The host markets a tributyrin product.
-
Butyrate: Health Benefits and Side Effects - Stephen Rose
Narrative tour of fermentation, receptors, colon-cell energy use, and the possibility that excess butyrate is not uniformly benign.
-
Interview on the aging microbiome; one segment is fiber feeding butyrate-producing bacteria. The guest co-founded a microbiome company.
-
Best Tools for Gut Health & Weight Loss – Dr. Chris Thompson - Andrew Huberman
Guest interview on gut health and weight, including fermented foods, microbial diversity, and butyrate.
Life Extension did not have a dedicated butyrate overview. A diverticular-disease protocol includes a butyrate subsection on one oral trial. Other hits were supplement catalog pages, which are product listings, or short mentions inside articles about prebiotic fiber.
Grokipedia
-
Primary Grokipedia entry for the four-carbon acid, covering identity, production, and biological roles under the chemical name.
Examine
-
Examine’s supplement page on dose, gut-health use, and side effects, with its trial database entry centered on ulcerative colitis.
ConsumerLab
-
Butyrate Supplements for Gut Health: Does butyric acid really work and is it safe?
Independent summary of forms (sodium, calcium-magnesium, tributyrin), trial limits, sodium load, and tolerability.
Systematic Reviews
Human systematic reviews of butyrate in colitis, fatty liver, depression, and stomach-infection treatment, plus the enema trial review. No systematic review of supplement harms was found, so blood-pressure and high-dose tolerability findings are unrepresented here.
-
Sodium Butyrate Therapy in Ulcerative Colitis: A Systematic Review of Preclinical and Clinical Evidence. - Golea et al., 2026
Ten clinical studies of oral or rectal sodium butyrate in ulcerative colitis; adult oral results look encouraging but uneven.
-
Eight randomized enema trials in ulcerative colitis; little consistent effect on disease activity or endoscopy.
-
The Role of Butyrate in People with Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Metabolic Comorbidities: A Systematic Review. - González-González et al., 2026
Seven observational studies: lower butyrate and fewer producing bacteria track with fatty liver. Not a supplement trial.
-
From gut to glee: Is butyrate a promising antidepressant? A systematic review and mechanistic insights. - Korenblik et al., 2026
Thirty-two animal studies are mostly favorable. Of two human trials, one is null and one is in colitis.
-
[Efficacy of butyric acid inclusion in eradication regimens for Helicobacter pylori infection: a meta-analysis of controlled trials.] - Andreev et al., 2021
Six trials (736 people): adding butyric acid raised Helicobacter pylori clearance (a stomach bacterium) and cut early diarrhea.
Mechanism of Action
Butyrate is a four-carbon short-chain fatty acid (SCFA) made when colon bacteria ferment fiber. Oral salts supply the same anion. Colon lining cells oxidize most of it as fuel. What remains can signal through free fatty acid receptor 2 (FFAR2), free fatty acid receptor 3 (FFAR3), and hydroxycarboxylic acid receptor 2 (HCAR2). Those receptors support mucus, the seals between lining cells, regulatory immune cells, and release of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), hormones tied to insulin and appetite. Butyrate also blocks histone deacetylase (HDAC), enzymes that keep DNA packed, which shifts inflammatory programs that include nuclear factor kappa-B (NF-κB), a protein complex that turns inflammatory genes on. A competing account, drawn from cell models, is that the same HDAC block pushes some transformed cells toward death (Heidor et al.). High-dose tributyrin in people with solid tumors did not produce objective responses (Edelman et al.). Which direction dominates depends on concentration, cell type, and colon delivery. Butyrate is not a one-target drug. Colon cells and the liver clear it by fatty-acid oxidation, not by the usual drug-metabolizing enzymes. After oral tributyrin, plasma butyrate peaked between 15 minutes and 3 hours and was gone by about 5 hours (Conley et al.). A later study called that half-life short (Edelman et al.).
Historical Context & Evolution
Butyrate was first known as the rancid note in butter, not as a medicine. Later physiology showed that cells lining the colon prefer it as fuel, and a shortage of that fuel was offered as one reason the lining fails in ulcerative colitis. That proposal led to butyrate enemas. A review of eight randomized enema trials found little consistent gain in disease activity, endoscopy, or histology, even when some biopsies showed local biological activity (Jamka et al.). Attention then shifted to oral products meant to survive the stomach: microencapsulated salts, and tributyrin, a fat that releases butyrate after digestion. Microbiome work tied species such as Faecalibacterium prausnitzii to higher butyrate and to calmer inflammatory bowel disease, and fiber research recast butyrate as one reason fermentable starch might matter for metabolic health. Separately, high-dose tributyrin was tested as a cancer differentiation agent. Nausea appeared at doses far above supplement use (Conley et al.), and tumors did not objectively shrink (Edelman et al.). The record is not a closed case. Enemas underperformed, some adult oral colitis trials look more favorable, and the metabolic and muscle findings are recent single studies.
Expected Benefits
High 🟩 🟩 🟩
Irritable Bowel Symptoms
Placebo-controlled trials found fewer irritable bowel symptoms. Calcium butyrate, 500 mg daily for 8 weeks, produced at least a 50 percent pain-score drop in 73 percent of children versus 3.8 percent on placebo (Cristofori et al.). In adults, microencapsulated sodium butyrate reduced pain during defecation, urgency, and bowel habit, but not overall pain severity (Banasiewicz et al.). In type 2 diabetes, 1.5 g daily for 12 weeks also reduced pain, diarrhea, and bloating (Panufnik et al.). Salts and doses differ, and the proposed action is colon-cell fuel.
Magnitude: 73 percent versus 3.8 percent achieved at least a 50 percent pain-score reduction at 8 weeks in children. The adult trial does not report a comparable percentage.
Helicobacter pylori Clearance When Added to Antibiotics
A meta-analysis of six controlled trials in 736 people found higher clearance when butyric acid was added to antibiotic therapy for Helicobacter pylori, and less diarrhea and bloating in the first week. The authors attribute the gain to people staying on the antibiotics as side effects fell, not to butyrate replacing those drugs. The trials tested add-on use (Andreev et al.).
Magnitude: Pooled clearance was 90.23 percent with butyric acid versus 65.69 percent without it.
Medium 🟩 🟩
Weight Loss Without Diabetes
In adults with overweight or obesity who did not have diabetes, oral sodium butyrate produced more weight loss than placebo when both groups followed the same reduced-calorie diet. The dose was 1,875 mg daily for 12 weeks. In participants who did have type 2 diabetes, weight loss did not differ from placebo. The clearest gap is this 12-week study of 46 people (Testa et al.). A second 8-week trial saw weight fall on 600 mg plus diet, but did not call butyrate alone beneficial (Amiri et al.).
Magnitude: About 3.8 kg greater weight loss than placebo over 12 weeks in adults without diabetes (mean loss 7.0 kg versus 3.2 kg).
Triglycerides and Tight Glucose Range in Type 2 Diabetes
In the same trial, participants with type 2 diabetes did not lose extra weight, but triglycerides fell and time spent in a tight glucose range rose, independent of weight change. An older four-arm trial found that sodium butyrate alone raised glucagon-like peptide-1 versus placebo, while fasting glucose fell clearly only when butyrate was combined with inulin (Roshanravan et al.). A 12-week trial of 1.5 g daily also reported lower glycated hemoglobin and a lower insulin-resistance index (Panufnik et al.).
Magnitude: Triglycerides changed by −0.36 mmol/L versus +0.08 mmol/L on placebo, and time in the 70–140 mg/dL glucose range rose by 9 percent, over 12 weeks.
Grip Strength and Physical Performance After Menopause
Postmenopausal women taking sodium butyrate as 570 mg capsules daily for 12 weeks improved handgrip strength and the short physical performance battery (a brief test of balance, gait, and chair stands) compared with the pattern in that trial’s placebo group. Plasma zonulin and lipopolysaccharide-binding protein, markers used as stand-ins for gut leak, fell, and those drops tracked the performance gains. This is one trial. It does not report the kilogram or point change (Qaisar et al.).
Magnitude: Handgrip and short physical performance battery scores improved over 12 weeks; the paper does not report the kilogram or point change.
Diverticulitis (Colon-Pouch Flare-Ups)
Adults with diverticulosis (small pouches in the colon wall) took microencapsulated sodium butyrate, 300 mg daily, for 12 months. Diverticulitis episodes were fewer than on placebo, and quality of life was rated higher. Fifty-two of 73 people finished, and no side effects were recorded. This is one trial. The proposed action is support of the colon lining (Krokowicz et al.).
Magnitude: Diverticulitis episodes were fewer than placebo over 12 months. The abstract does not report how many episodes occurred in each group.
Crohn’s Disease Activity
Adults with Crohn’s disease who added oral microencapsulated butyrate to usual care had lower disease activity in one randomized trial, and a stool inflammation marker fell (Facchin et al.). Quality of life rose in both Crohn’s disease and ulcerative colitis in that trial. The ulcerative colitis marker change was only marginal. This is a single trial, and butyrate was added to usual care rather than used alone.
Magnitude: Disease activity fell in the Crohn’s disease arm; the paper does not report the point change on the activity scale.
Low 🟩
Fatty Liver Index on a Butyrate-Containing Formula
Adults with fatty liver and metabolic syndrome took calcium butyrate 500 mg plus zinc and vitamin D, or placebo, once daily for 3 months. The fatty liver index improved versus placebo. The tablet was not butyrate alone, and this is one trial of 50 people (Fogacci et al.).
Magnitude: Fatty liver index fell versus placebo over 3 months. The report does not give the point change, and the tablet included zinc and vitamin D.
Ulcerative Colitis Activity ⚠️ Conflicted
One adult oral trial at 600 mg daily found more improvement than placebo (Karłowicz et al.). A pediatric trial (Pietrzak et al.) and enema trials (Jamka et al.) did not. Another trial found only a marginal marker change (Facchin et al.). Net reading: the adult oral signal is not confirmed.
Magnitude: 51 percent clinical improvement and 31.4 percent clinical remission at 8 weeks in one adult oral trial. Pediatric oral and adult enema results did not show that gain.
Depressive and Anxiety Symptoms ⚠️ Conflicted
A review found two human trials. One week of oral butyrate did not change mood in healthy men. Twelve weeks reduced depressive and anxiety symptoms in ulcerative colitis (Korenblik et al.). Net reading: a mood effect is not established outside that single colitis trial.
Magnitude: Symptom scores moved down in one 12-week colitis trial and did not move in a 1-week trial of healthy men. The review reports no pooled effect size.
Speculative 🟨
Cancer Prevention or Added Years of Life
No supplement-dose trial has a cancer or survival endpoint. Cell and animal work on tumor differentiation, and observational fiber studies, are not evidence that capsules prevent cancer or extend life.
Benefit-Modifying Factors
- Diabetes at baseline: Extra weight loss appeared in overweight adults without diabetes. In type 2 diabetes the measured changes were triglycerides and time in a tight glucose range, not extra weight loss.
- Baseline labs: No starting blood test is known to turn a benefit on or off. Body weight moved without diabetes. Triglycerides and time in a tight glucose range moved in type 2 diabetes.
- Gut diagnosis and age: Children had a large irritable-bowel pain response and no added colitis remission versus placebo at 300 mg. Adults had a narrower bowel response. Trials reached about 70 years, and no separate benefit is published for advanced age.
- Co-ingredients: The fatty liver index result used calcium butyrate plus zinc and vitamin D. Inulin plus butyrate, not butyrate alone, was what lowered fasting glucose in one diabetes trial.
- Sex: No sex-specific benefit is established. The grip trial enrolled only postmenopausal women. The weight trial enrolled both sexes and did not publish a separate dose or effect by sex.
- Host genes: No human gene test is known to turn the benefit on or off. Lower abundance of butyrate-producing bacteria is a microbial pattern, reported in fatty liver, not a host polymorphism.
- Fiber intake: People who eat little fermentable fiber make less butyrate. A capsule does not reproduce the other acids and the bulk that fermentation also produces.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: grade 3 nausea comes from a single phase-1 tributyrin escalation, and the pressure rise comes from one drug-withdrawal trial.
Medium 🟥 🟥
Nausea and Related Symptoms at High Tributyrin Doses
In a phase 1 study, 13 people with solid tumors took oral tributyrin at 50–400 mg/kg/day, and grade 3 events were nausea, vomiting, and myalgia (muscle pain) (Conley et al.). Grade 1–2 events included diarrhea, cramping, headache, odor, and fatigue. Plasma butyrate was gone by 5 hours. A later three-times-daily study (150–200 mg/kg) found no dose-limiting toxicity and stopped for capsule count (Edelman et al.). These doses dwarf the 0.3–4 g supplement range.
Magnitude: Grade 3 nausea, vomiting, and myalgia occurred at 50–400 mg/kg/day of tributyrin. Supplement-dose trials often recorded no adverse events.
Low 🟥
Blood Pressure Change ⚠️ Conflicted
Oral butyrate for 4 weeks, after blood-pressure drugs were stopped, raised daytime pressure versus placebo (Verhaar et al.). A diabetes trial found lower diastolic pressure (Roshanravan et al.). A butyrate enema lowered systolic pressure (Hogue et al.). Net reading: direction depends on route and on whether those drugs were stopped.
Magnitude: Daytime systolic pressure rose 9.63 mm Hg over 4 weeks when blood-pressure drugs were stopped. An enema trial and a diabetes trial moved pressure the other way. The literature does not give one shared figure.
Speculative 🟨
Off-Target Gene Effects at High Plasma Levels
Tributyrin can briefly raise plasma butyrate into a range that blocks histone deacetylase in cell dishes. No human outcome shows harm from that effect at supplement doses. The basis is mechanistic only.
Risk-Modifying Factors
- Blood-pressure drugs: The pressure rise was measured after those drugs were stopped. People who stay on treatment were not the studied group.
- Sodium load and heart failure: Sodium butyrate adds sodium. A recruiting trial excludes heart failure, salt-restricted diets, and serum sodium above 145 mEq/L (milliequivalents per liter).
- Dose and form: Grade 3 nausea was seen at tributyrin doses of 50–400 mg/kg/day, not at capsule doses of a few grams. Calcium and tributyrin forms avoid the sodium salt.
- Age: Children in a colitis trial reported no adverse events at 300 mg daily. The pressure trial’s mean age was about 59 years. No separate older-adult harm rate is published.
- Sex: No sex difference in adverse events is established. The pressure trial was 56.5 percent women and did not split harm by sex.
- Starting blood pressure: Office systolic pressure averaged about 144 mm Hg in the trial that found a rise. A normal starting pressure was not that trial’s population.
Key Interactions & Contraindications
- Blood-pressure drugs (lisinopril, amlodipine): Caution. Daytime pressure rose when these drugs were stopped during oral butyrate. Consequence: higher systolic and diastolic readings. Mitigation: usual therapy stays in place, with a pressure check at about 4 weeks.
- Histone deacetylase inhibitors (vorinostat): Caution. A radiation trial excludes combining them with short-chain fatty acids because both loosen DNA packing. Consequence: a stronger, untested combined effect. The protocol keeps the two apart.
- Sodium-containing products: Caution. Sodium butyrate itself is a sodium salt, and sodium antacids add more. Consequence: higher sodium intake on top of the pressure signal. Mitigation: a calcium salt or tributyrin removes that sodium.
- Inulin and fermentable fiber: Additive, monitor. Inulin plus butyrate raised glucagon-like peptide-1 and was the arm that lowered fasting glucose. Fiber also feeds bacterial butyrate production. Consequence: a larger metabolic signal, not a documented toxicity.
- Antibiotics: Indirect, monitor. Broad antibiotics (amoxicillin, ciprofloxacin) can cut the bacteria that make butyrate, so endogenous supply falls while a capsule does not. No interaction dose change is established.
- Other over-the-counter drugs: Monitor. No specific interaction is documented beyond sodium load. Consequence of ignoring sodium sources is a higher daily sodium total.
Populations who should avoid Butyrate:
- Congestive heart failure, or a prescribed salt-restricted diet. A recruiting short-chain fatty acid trial excludes both because of sodium.
- Serum sodium above 145 mEq/L. The same trial uses that threshold as an exclusion.
- Pregnancy or breastfeeding. Supplement trials and the radiation trial exclude these groups, and a human pregnancy outcome dataset is not available.
- Known intolerance or allergy to butyrate, including prior vomiting or rash on a butyrate product.
Risk Mitigation Strategies
- Keep blood-pressure drugs: The measured pressure rise occurred after those drugs were stopped. Staying on existing therapy, and rechecking pressure within 4 weeks, addresses that setting.
- Stay in the gram range: Grade 3 nausea, vomiting, and myalgia were recorded at tributyrin doses of 50–400 mg/kg/day. Supplement trials used roughly 0.3–4 g daily.
- Prefer a low-sodium form if salt is restricted: Calcium butyrate or tributyrin avoids the sodium in sodium butyrate, which matters in heart failure and salt-restricted diets.
- Use a colon-release product: Microencapsulation or an enteric coat is what the positive bowel trials used. Free acid is more likely to cause odor and upper-gut upset.
- New odor, cramping, or headache: Those were grade 1–2 events at high tributyrin doses. Ending the exposure removes them. Supplement trials used no taper.
Therapeutic Protocol
- Adult oral sodium butyrate: Trials have used 600 mg daily (300 mg twice daily) for 8 weeks in colitis, 1.5 g daily for 12 weeks, and 1,875 mg daily for 12 weeks with a reduced-calorie diet.
- Calcium butyrate: Pediatric irritable bowel dosing was 500 mg daily for 8 weeks. A liver-fat tablet used 500 mg plus zinc and vitamin D, so that regimen is not butyrate alone.
- Tributyrin: Cancer-trial doses of 50–400 mg/kg/day are not supplement practice. Plasma butyrate after tributyrin was gone by about 5 hours, which is why those studies moved toward three daily doses.
- Time of day: With food, split across the day. One liver-fat protocol places sachets morning, midday, and evening. A single uncoated dose is a poor match to the short plasma presence.
- Half-life: Short. After oral tributyrin, the peak was at 15 minutes to 3 hours and the level was undetectable by 5 hours. Colon cells consume much of a colon-released dose before it circulates.
- Split versus once daily: Split dosing follows the short half-life. Once-daily dosing was the pattern of some 570 mg capsule use, but colon-targeted products in other trials were divided.
- Genes: No host-gene test sets the dose. Butyrate-producer abundance is a stool finding, not a pharmacogenetic dose rule.
- Sex: No sex-specific dose is established. Grip data are from postmenopausal women only. The weight trial mixed sexes on one dose.
- Age: Metabolic trials enrolled adults, including people around 60 years in the pressure study. Children used 300–500 mg daily. No separate dose for advanced age is published.
- Baseline markers: Weight change is the outcome to watch in overweight adults without diabetes. Triglycerides and glucose range are the outcomes in type 2 diabetes. Starting pressure frames the conflicting pressure results.
- Other illnesses: Colitis trials added butyrate to usual care rather than replacing it. Heart failure and salt restriction were exclusions, not studied indications.
Discontinuation & Cycling
- How long: Studied courses ran 4–12 weeks, not a lifelong prescription. Bacterial production continues if fermentable fiber intake continues after the capsules stop.
- Withdrawal: No withdrawal syndrome is described. Colitis, diabetes, and irritable bowel trials do not report rebound symptoms at the planned stop.
- Taper: No taper is described. Exposure was stopped at the end-of-study visit in the randomized trials.
- Cycling: On-off cycling has not been tested as a way to preserve an effect. The evidence is for continuous use across the trial window only.
- One agent: This review treats butyrate as a single intervention. There is no paired drug that must be stopped on a different schedule.
Sourcing and Quality
- Release form: Microencapsulated or enteric-coated sodium or calcium butyrate, or tributyrin, matches the products used when colon delivery was the goal. Free butyric acid smells like rancid butter and is absorbed earlier.
- Name check: Beta-hydroxy-beta-methylbutyrate (HMB), a leucine-related muscle compound, and the ketone beta-hydroxybutyrate are not butyrate. Specific products name the salt or tributyrin.
- Testing: In the United States this is a dietary supplement, not a pre-approved drug. A USP (United States Pharmacopeia) or NSF (NSF International) content assay is the practical check on dose and contaminants.
- Products named publicly: ConsumerLab’s overview discusses BodyBio sodium butyrate and Healus tributyrin. That mention is not a passed laboratory ranking.
- Odor: A vomit-like smell from a coated product suggests the coat has failed. Cool, dry storage slows that breakdown.
Practical Considerations
- Time to effect: Pain during defecation moved by 4 weeks, and urgency and bowel habit by 12 weeks, in one adult irritable bowel trial. Weight and triglycerides were read at 12 weeks. Fatty liver index was read at 3 months.
- Pitfalls: Mixing up butyrate with HMB or with ketone salts; treating a zinc-plus-vitamin-D tablet as pure butyrate; expecting uncoated powder to act in the colon; reading enema history as if it were the oral trials.
- Regulatory status: Sold in the United States as a dietary supplement. Not approved to treat colitis, diabetes, fatty liver, or hypertension.
- Access: Widely sold and not exceptionally expensive. The limit in the evidence is the size and disagreement of the trials, not price or scarcity.
Interaction with Foundational Habits
- Sleep: None established. Supplement trials do not describe insomnia or a required bedtime dose. A colitis trial measured sleep after butyrate, but that disease setting is not a general sleep result, and no mechanism for a sleep change is settled.
- Nutrition: Potentiating for endogenous production. Bacteria make butyrate from fermentable fiber and resistant starch, so legumes, oats, and cooled cooked starch raise production. A capsule does not replace that fermentation or the other acids it yields.
- Exercise: Indirect, possibly potentiating. Training has been tied to more butyrate-producing bacteria without a supplement. No trial shows blunted muscle growth. The postmenopausal trial found higher grip strength, not lower.
- Stress management: None established. Gut-barrier signaling is a proposed link to stress-related gut symptoms, but no supplement trial shows a change in perceived stress. Butyrate does not stand in for a stress practice.
Monitoring Protocol & Defining Success
Before the first dose, a seated morning blood pressure, body weight, and a fasting blood draw for triglycerides, glucose, and glycated hemoglobin set the personal baseline. Those are the outcomes the trials actually moved, in different subgroups. People with bowel symptoms can add a symptom score and, if inflammatory bowel disease is already diagnosed, fecal calprotectin through their usual care. The draw is fasting. Pressure is repeated at about 4 weeks because that is when the drug-withdrawal trial saw a rise. Weight, triglycerides, glucose, and glycated hemoglobin are repeated at 12 weeks, then every 6–12 months if use continues. A rising pressure or new headache, cramping, or odor is the pattern that matched early adverse events in high-dose studies. Success is a change from the person’s own baseline on the outcome that matched their situation, not a universal laboratory target.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Blood pressure | Below 120/80 mm Hg | Trials moved pressure in both directions | Conventional hypertension labeling often starts near 130/80 mm Hg. Seated, after 5 minutes, morning. |
| Fasting triglycerides | Below 100 mg/dL | Fell in one diabetes trial | Conventional reference is often below 150 mg/dL. Fasting draw. |
| Glycated hemoglobin | Below 5.4 percent | Longer glucose exposure | Often reported as HbA1c. Conventional non-diabetes cutoff is often below 5.7 percent. Not a fasting-hour test. |
| Fasting glucose | 75–90 mg/dL | Pairs with glycated hemoglobin | Conventional fasting range is often 70–99 mg/dL. |
| High-sensitivity C-reactive protein | Below 1.0 mg/L | Background inflammation | Often abbreviated hs-CRP. Conventional average-risk cutoff is often below 3.0 mg/L. |
| Body weight | Change from personal baseline | Non-diabetes trial outcome | No single kilogram target. Same scale, same time of day. |
Qualitative markers:
- Bowel comfort: pain with defecation, urgency, bloating, and stool form across 4–12 weeks.
- Odor, cramping, nausea, or a new headache after a dose change.
- Daytime energy and, in postmenopausal women, ease of grip and a short walk.
- Sleep quality, recorded because a colitis trial measured it, without a settled direction.
Emerging Research
- Liver fat in type 1 diabetes: BEAM-T1D is not yet recruiting, about 200 adults, factorial: 2.25 g daily microencapsulated sodium butyrate, lifestyle change, both, or neither. Primary endpoint is liver fat by elastography over 6 months. A null result would weaken fatty-liver claims built on combination tablets.
- Gut toxicity during radiation: LCCC2032 is recruiting, about 122 adults, phase 1/2. Sodium butyrate plus sodium propionate, 4–6 g daily, versus placebo around abdominal or pelvic radiation. Endpoint is gut toxicity. It is a two-acid mix, and the result could favor or weaken gut-protection claims.
- Blood-pressure direction: A single 4-week trial found a daytime pressure rise after drugs were stopped (Verhaar et al.). A diabetes trial found a lower diastolic pressure (Roshanravan et al.). A larger trial that keeps usual drugs could erase or confirm the harm signal.
Conclusion
Butyrate is a four-carbon fatty acid that colon bacteria make from fermentable fiber and that is also sold as oral salts and as a fat that releases butyrate after digestion. Human trials have reported narrow changes in bowel symptoms, body weight, blood fats, or a liver-fat score. Irritable bowel symptom scores improved clearly in a pediatric trial and only on selected symptoms in adult trials. Extra weight loss appeared in overweight adults without diabetes. In diabetes, blood fats, glucose range, or the longer-term glucose marker moved, not extra weight. A postmenopausal trial found better grip and a short performance score. One trial recorded fewer flare-ups in adults who already had small colon pouches. A fatty-liver score improved on a tablet that also contained zinc and vitamin D, so that result is not butyrate alone. Colitis results conflict by age and by whether the dose was an enema or an oral capsule. One Crohn’s disease trial found lower activity on added butyrate. Added to antibiotics, clearance of a common stomach bacterium was higher. Blood pressure has moved in opposite directions, including a rise after blood-pressure drugs were stopped. High doses of that fat caused nausea. Evidence that capsules extend life or prevent cancer is absent. Much of the base is small unreplicated trials, plus laboratory studies on how it acts. The main trials are academic. Supplement sellers still have a commercial interest in broader claims than those trials support, and the unfavorable pressure result does not come from that commercial interest.